The Changing Paradigm of IBD

Recent clinical data indicates a significant shift in the inflammatory bowel disease (IBD) landscape. Traditionally, clinicians viewed IBD as a malabsorptive condition that led to an undernourished state. However, the disease is now evolving into one where obesity is a prevalent and challenging comorbidity. This paradigm shift requires a renewed focus on obesity in IBD management to address emerging metabolic complications that affect long-term outcomes.

Linking Obesity in IBD Management to Metabolic Risks

A large-scale retrospective cohort study from the binational Crohns Colitis Care registry in Australia and New Zealand recently highlighted these trends. The findings show that a high percentage of the IBD cohort is now classified as overweight or obese. Notably, researchers found that an increasing body mass index (BMI) was strongly associated with older age and several cardiometabolic comorbidities. These include type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD.

Furthermore, the presence of excess adipose tissue complicates the inflammatory profile of IBD. Visceral fat acts as an active endocrine organ, releasing pro-inflammatory cytokines that may worsen gut inflammation. Consequently, patients with a higher BMI may experience a more complex disease course. Physicians must also consider that obesity can influence the pharmacokinetics of various IBD therapies, potentially necessitating dose adjustments to maintain clinical remission.

Clinical Implications for the Asian Subcontinent

While the study focused on Australasian data, the results are highly relevant to the Indian context. India is currently witnessing a dual rise in IBD incidence and metabolic syndrome. As lifestyle factors become more Westernized, the "obese IBD" phenotype is becoming increasingly common in urban clinical practice. Therefore, integrated care involving gastroenterologists and endocrinologists is essential. Specifically, early screening for MASLD and diabetes should become a routine part of IBD follow-ups to mitigate secondary health risks.

Frequently Asked Questions

Is obesity common in patients with IBD?

Yes, recent studies show that 15% to 40% of adult IBD patients are obese, and another 20% to 40% are overweight, marking a major shift from the traditional undernourished IBD phenotype.

How does a high BMI affect IBD treatment?

High BMI is linked to an increased risk of cardiometabolic comorbidities like diabetes and liver disease. Additionally, it may impact the efficacy of fixed-dose biologic therapies, often requiring more frequent dose escalations.

What is the link between IBD and MASLD?

IBD and metabolic dysfunction-associated steatotic liver disease (MASLD) share a complex gut-liver axis relationship. Chronic intestinal inflammation and changes in gut microbiota can accelerate the development of liver fat accumulation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Kaazan P et al. The trend of obesity and inflammatory bowel disease in Australia and New Zealand: a bi-nation cohort study. Intern Med J. 2026 May 05. doi: 10.1111/imj.70454. PMID: 42085713.

2. Kedia S et al. Rising Incidence of Inflammatory Bowel Disease in the Asian Subcontinent—An Exploration of Causative Factors. MDPI. 2024; 13(12): 1024.

3. Kaazan P et al. The Impact of Obesity on Inflammatory Bowel Disease. Biomedicines. 2023; 11(12): 3256.